Patient AmTrust investors unaligned with the controlling Karfunkel-Zyskind family may yet find themselves the beneficiaries of Carl Icahn’s protests over the deal being offered to take the insurer private.
Patient AmTrust investors unaligned with the controlling Karfunkel-Zyskind family may yet find themselves the beneficiaries of Carl Icahn’s protests over the deal being offered to take the insurer private.